e5 152 Murakami CS, Louie W, Chan GS, et al Biliary obstruction in hematopoietic cell transplant recipients an uncommon diagnosis with specific causes Bone Marrow Transplant 1999;23(9) 921 927 153 Jac[.]
e5 152 Murakami CS, Louie W, Chan GS, et al Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes Bone Marrow Transplant 1999;23(9):921-927 153 Jacobs P, Miller JL, Uys CJ, Dietrich BE Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia S Afr Med J 1979;55(1):5-10 154 Miano M, Faraci M, Dini G, Bordigoni P Early complications following haematopoietic SCT in children Bone Marrow Transplant 2008;41(suppl 2):S39-S42 155 Shulman HM, McDonald GB, Matthews D, et al An analysis of hepatic veno-occlusive disease and cetrilobular hepatic degeneration following bone marrow transplantation Gastroenterology 1980;79:1178-1191 156 Shulman HM, Gown AM, Nugent DJ Hepatic veno-occlusive disease after bone marrow transplantation Immunohistochemical identification of the material within occluded central venules Am J Pathol 1987;127(3):549-558 157 McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors Hepatology 1984;4:116-122 158 Jones R, Lee K, Beschorner W Veno-occlusive disease of the liver following bone marrow transplantation Transplantation 1987;44:778-783 159 McDonald GB, Hinds MS, Fisher LD, et al Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993;118(4):255-267 160 Cesaro S, Pillon M, Talenti E, et al A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation Haematologica 2005;90(10):1396-1404 161 Essell JH, Thompson JM, Harman GS, et al Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide Blood 1992;79(10):2784-2788 162 Wingard JR, Niehaus CS, Peterson DE, et al Oral mucositis after bone marrow transplantation A marker of treatment toxicity and predictor of hepatic veno-occlusive disease Oral Surg Oral Med Oral Pathol 1991;72(4):419-424 163 Wingard JR, Mellits ED, Jones RJ, et al Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients Bone Marrow Transplant 1989;4(6):685689 164 Jastaniah W, Harmatz P, Pakbaz Z, Fischer R, Vichinsky E, Walters MC Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies Pediatr Blood Cancer 2008;50(2):319-324 165 Cheuk DK, Wang P, Lee TL, et al Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation Bone Marrow Transplant 2007;40(10):935-944 166 Cacchione A, LeMaitre A, Couanet DV, et al Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen Bone Marrow Transplant 2008;42(7):449-454 167 Platzbecker U, von Bonin M, Goekkurt E, et al Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial Biol Blood Marrow Transplant 2009;15(1):101-108 168 Vinayek R, Demetris J, Rakela J Liver disease in hematopoietic stem cell transplant recipients In: Ball E, Lister J, Ping L, editors: Hematopoietic Stem Cell Therapy Philadelphia: Churchill Livingstone; 2000 169 Bajwa RPS, Mahadeo KM, Taragin BH, et al Consensus report by pediatric acute lung injury and sepsis investigators and pediatric bone marrow transplantation consortium joint working committees: Supportive care guidelines for management of veno-occlusive disease in children and adolescents, Part 1: Focus on investigations, prophylaxis, and specific treatment Biol Blood Marrow Transplant 2017; 23:1817-1825 170 Dignan FL, Wynn RF, Hadzic N, et al BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation Br J Haematol 2013;163(4):444-457 171 Bearman SI The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 1995;85(11):3005-3020 172 Shulman HM, Gooley T, Dudley MD, et al Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients Transplantation 1995; 59(7):1015-1022 173 Carreras E, Granena A, Navasa M, et al Transjugular liver biopsy in BMT Bone Marrow Transplant 1993;11(1):21-26 174 Shulman HM, McDonald GB Transvenous liver biopsies and pressure measurements in bone marrow transplant recipients Hepatology 1992;16:148 175 Mahadeo KM, McArthur J, Adams RH, et al Consensus report by pediatric acute lung injury and sepsis investigators and pediatric bone marrow transplantation consortium joint working committees: Supportive care guidelines for management of veno-occlusive disease in children and adolescents, Part 2: Focus on ascites, fluid and electrolytes, renal and transfusion issues Biol Blood Marrow Transplant 2017;23:2023-2033 176 Ovchinsly N, Frazier W, Auletta JJ, et al Consensus report by pediatric acute lung injury and sepsis investigators and pediatric bone marrow transplantation consortium joint working committees: Supportive care guidelines for management of veno-occlusive disease in children and adolescents, Part 3: Focus on cardiorespiratory dysfunction , infections, liver dysfunction and delirium Biol Blood Marrow Transplant 2018;24:207-218 177 Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis Bone Marrow Transplant 2006;37(7):677-686 178 Essell JH, Schroeder MT, Harman GS, et al Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation A randomized, double-blind, placebo-controlled trial Ann Intern Med 1998;128(12 Pt 1):975-981 179 Ohashi K, Tanabe J, Watanabe R, et al The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation Am J Hematol 2000;64(1):32-38 180 Qureshi A, Marshall L, Lancaster D Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children Pediatr Blood Cancer 2008;50(4):831-832 181 Dignan F, Gujral D, Ethell M, et al Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease Bone Marrow Transplant 2007;40(1):79-82 182 Corbacioglu S, Greil J, Peters C, et al Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention Bone Marrow Transplant 2004;33(2):189-195 183 Bulley SR, Strahm B, Doyle J, Dupuis LL Defibrotide for the treatment of hepatic veno-occlusive disease in children Pediatr Blood Cancer 2007;48:700-704 184 Richardson PG, Murakami C, Jin Z, et al Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive ofoutcome Blood 2002;100: 4337-4343 e6 185 Richardson PG, Elias AD, Krishnan A, et al Treatment of severe venoocclusive disease with defibrotide—compassionate use results in response without significant toxicity in a high-risk population Blood 1998;92:737-744 186 Richardson PG, Soiffer RJ, Antin JH, et al Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial Biol Blood Marrow Transplant 2010;16(7):10051017 187 Richardson PG, Riches ML, Kernan NA, et al Phase trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure Blood 2016;127:1656-1665 188 Lee JH, Lim GY, Im SA, Chung NG, Hahn ST Gastrointestinal complications following hematopoietic stem cell transplantation in children Korean J Radiol 2008;9(5):449-457 189 Barker CC, Anderson RA, Sauve RS, Butzner JD GI complications in pediatric patients post-BMT Bone Marrow Transplant 2005;36(1):51-58 190 Shamberger RC, Weinstein HJ, Delorey MJ, Levey RH The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia Cancer 1986;57(3):603-609 191 Otaibi AA, Barker C, Anderson R, Sigalet DL Neutropenic enterocolitis (typhlitis) after pediatric bone marrow transplant J Pediatr Surg 2002;37(5):770-772 192 Jones B, Fishman EK, Kramer SS, et al Computed tomography of gastrointestinal inflammation after bone marrow transplantation AJR Am J Roentgenol 1986;146(4):691-695 193 Donnelly LF, Morris CL Acute graft-versus-host disease in children: abdominal CT findings Radiology 1996;199(1):265-268 194 Mentzel HJ, Kentouche K, Kosmehl H, et al US and MRI of gastrointestinal graft-versus-host disease Pediatr Radiol 2002;32(3):195-198 195 Fisk JD, Shulman HM, Greening RR, McDonald GB, Sale GE, Thomas ED Gastrointestinal radiographic features of human graftvs.-host disease AJR Am J Roentgenol 1981;136(2):329-336 196 Jodele S, Dandoy CE, Myers KC, et al New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Transfus Apher Sci 2016;54:181-190 197 Werlin SL, Casper J, Antonson D, Calabro C Pancreatitis associated with bone marrow transplantation in children Bone Marrow Transpl 1992;10(1):65-69 198 Lang P, Handgretinger R Haploidentical SCT in children: an update and future perspectives Bone Marrow Transplant 2008;42(suppl 2):S54-S59 199 Cutler C, Antin JH Peripheral blood stem cells for allogeneic transplantation: a review Stem Cells 2001;19(2):108-117 200 Sauter C, Barker JN Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Curr Opin Hematol 2008;15(6):568-575 201 Smith TJ, Khatcheressian J, Lyman GH, et al 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 2006;24(19):3187-3205 202 Parkman R, Weinberg KI Immunological reconstitution following bone marrow transplantation Immunol Rev 1997;157:73-78 203 Small TN, Papadopoulos EB, Boulad F, et al Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions Blood 1999;93(2):467-480 204 Avigan D, Pirofski LA, Lazarus HM Vaccination against infectious disease following hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2001;7(3):171-183 205 Pizzo PA, Hathorn JW, Hiemenz J, et al A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia N Engl J Med 1986;315(9):552-558 206 De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer A multicenter randomized trial The Intercontinental Antimicrobial Study Group Ann Intern Med 1994;120(10):834-844 207 Winston DJ, Ho WG, Bruckner DA, Champlin RE Beta-lactam antibiotic therapy in febrile granulocytopenic patients A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone Ann Intern Med 1991;115(11):849-859 208 Slavin MA, Osborne B, Adams R, et al Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study J Infect Dis 1995;171(6):1545-1552 209 Kaste SC, Kaufman RA, Sunkara A, et al Routine pre- and posthematopoietic stem cell transplant computed tomography of the abdomen for detecting invasive fungal infection has limited value Biol Blood Marrow Transplant 2015;21(6):1132-1135 210 Jung J, Kim MY, Lee HJ, et al Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis Clin Microbiol Infect 2015;21(7):684e.11-8 211 Wald A, Leisenring W, van Burik JA, Bowden RA Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation J Infect Dis 1997;175(6):14591466 212 Goodrich JM, Mori M, Gleaves CA, et al Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation N Engl J Med 1991;325(23):16011607 213 Meyers JD, Flournoy N, Thomas ED Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 1986;153(3):478-488 214 Schmidt GM, Kovacs A, Zaia JA, et al Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirusassociated interstitial pneumonia in bone marrow allograft recipients Transplantation 1988;46(6):905-907 215 Aschen J, Ringden O, Ljungman P Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients Scand J Infect Dis 1992;24:143-150 216 Bacigalupo A, van Lint MT, Tedone E, et al Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir Bone Marrow Transplant 1994;13(6): 753-758 217 Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients Semin Respir Crit Care Med 2011;32(4):471-493 218 Breuer S, Rauch M, Matthes-Martin S, Lion T Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients Mol Diagn Ther 2012;16(2):63-77 219 Pollack M, Heugel J, Xie H, et al An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients Biol Blood Marrow Transplant 2011;17(5):664-673 220 Kim YJ, Boeckh M, Englund JA Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection Semin Respir Crit Care Med 2007;28(2):222-242 221 Boeckh M, Erard V, Zerr D, Englund J Emerging viral infections after hematopoietic cell transplantation Pediatr Transplant 2005;9(suppl 7):48-54 222 Hanley PJ, Cruz CR, Savoldo B, et al Functionally active virusspecific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes Blood 2009;114(9):1958-1967 223 Hanley PJ, Melenhorst JJ, Nikiforow S, et al CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo Sci Transl Med 2015;7(285):285ra63 e7 224 Sukdolak C, Tischer S, Dieks D, et al CMV-, EBV- and ADVspecific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome Biol Blood Marrow Transplant 2013;19(10):1480-1492 225 Locatelli F, Lucarelli B, Merli P Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation Expert Opin Pharmacother 2014;15(1):23-36 226 Wolff SN Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation Bone Marrow Transplant 2002;29(7):545-552 227 Mattsson J, Ringden O, Storb R Graft failure after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 2008;14(suppl 1):165-170 228 Corash L, Lin L Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease Bone Marrow Transplant 2004;33(1):1-7 229 Vamvakas EC Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis Transfus Med Rev 2005;19(3):181-199 230 Scholl S, Klink A, Mugge LO, Schilling K, Hoffken K, Sayer HG Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch Transfusion 2005;45(10):1676-1683 231 Jodele S, Laskin BL, Dandoy CE, et al A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury Blood Rev 2015;29:191-204 232 Jodele S, Davies SM, Lane A, et al Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults Blood 2014;124:645-653 233 Cho BS, Yahng SA, Lee SE, et al Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation Transplantation 2010;90:918-926 234 Jodele S, Licht C, Goebel J, et al Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy Blood 2013;122:2003-2070 235 Jodele S, Fukuda T, Vinks A, et al Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy Biol Blood Marrow Transplant 2014;20;518-525 236 Guinan EC, Tarbell NJ, Niemeyer CM, Sallan SE, Weinstein HJ Intravascular hemolysis and renal insufficiency after bone marrow transplantation Blood 1988;72(2):451-455 237 Choi CM, Schmaier AH, Snell MR, Lazarus HM Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment Drugs 2009;69(2):183-198 238 Hale GA, Bowman LC, Rochester RJ, et al Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children Biol Blood Marrow Transplant 2005;11(11):912-920 239 Pullarkat V Iron toxicity in hematopoietic stem cell transplantation: Strike while the iron is labile Acta Haematol 2014;131(4):220221 240 de Witte T The role of iron in patients after bone marrow transplantation Blood Rev 2008;22(suppl 2):S22-S28 241 Cappelli B, Chiesa R, Evangelio C, et al Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous busulphan Br J Haematol 2009;147(4):554-560 242 Majhail NS, Lazarus HM, Burns LJ Iron overload in hematopoietic cell transplantation Bone Marrow Transplant 2008;41(12):9971003 243 Kim YR, Kim JS, Cheong JW, Song JW, Min YH Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies Acta Haematol 2008; 120(3):182-189 244 Pullarkat V, Blanchard S, Tegtmeier B, et al Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2008;42(12):799-805 245 Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content Blood 2013;122(9):1678-1684 246 Au WY, Lam WM, Chu WC, et al A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels Transplant Proc 2007;39(10):33693374 247 Meo A, Ruggeri A, La Rosa MA, Zanghi L, Morabito N, Duca L Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation Hemoglobin 2006;30(1):131-137 248 Cho SJ, Lee SJ, Yoo ES, et al Iron removal with phlebotomy and recombinant human erythropoietin in secondary hemochromatosis after allogeneic bone marrow transplantation Pediatr Int 2006;48(2):174-177 249 Li CK, Lai DH, Shing MM, Chik KW, Lee V, Yuen PM Early iron reduction programme for thalassaemia patients after bone marrow transplantation Bone Marrow Transplant 2000;25(6):653-656 250 Ferrara JL, Levine JE, Reddy P, Holler E Graft-versus-host disease Lancet 2009;373(9674):1550-1561 251 Ferrara JL, Reddy P Pathophysiology of graft-versus-host disease Semin Hematol 2006;43(1):3-10 252 Jagasia MH, Greinix HT, Arora M, et al National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I The 2014 Diagnosis and Staging Working Group report Biol Blood Marrow Transplant 2015;21(3):389-401 253 Picardi M, Selleri C, Rotoli B Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations Bone Marrow Transplant 1999;24(2):173-177 254 Weber C, Schaper J, Tibussek D, et al Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation Bone Marrow Transplant 2008;41(3):253-259 255 Schmidt K, Schulz AS, Debatin KM, Friedrich W, Classen CF CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors Pediatr Blood Cancer 2008;50(2):331-336 256 Woodard P, Helton K, McDaniel H, et al Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis Bone Marrow Transplant 2004;33(11):1151-1157 257 Eliashiv S, Brenner T, Abramsky O, et al Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation Bone Marrow Transplant 1991;8(4):315-317 258 Zaja F, Barillari G, Russo D, Silvestri F, Fanin R, Baccarani M Myasthenia gravis after allogeneic bone marrow transplantation A case report and a review of the literature Acta Neurol Scand 1997;96(4):256-259 259 Anderson BA, Young PV, Kean WF, Ludwin SK, Galbraith PR, Anastassiades TP Polymyositis in chronic graft vs host disease A case report Arch Neurol 1982;39(3):188-190 260 Iguchi A, Kobayashi R, Yoshida M, et al Neurological complications after stem cell transplantation in childhood Bone Marrow Transplant 1999;24(6):647-652 261 Graus F, Saiz A, Sierra J, et al Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study Neurology 1996;46(4):1004-1009 262 Guerrero A, Perez-Simon JA, Gutierrez N, et al Neurological complications after autologous stem cell transplantation Eur Neurol 1999;41(1):48-50 263 Uckan D, Cetin M, Yigitkanli I, et al Life-threatening neurological complications after bone marrow transplantation in children Bone Marrow Transplant 2005;35(1):71-76 e8 264 Martino R, Maertens J, Bretagne S, et al Toxoplasmosis after hematopoietic stem cell transplantation Clin Infect Dis 2000;31(5):1188-1195 265 Marr KA, Carter RA, Boeckh M, Martin P, Corey L Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors Blood 2002;100(13):4358-4366 266 Furlong T, Storb R, Anasetti C, et al Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities Bone Marrow Transplant 2000;26(9):985-991 267 de Medeiros BC, de Medeiros CR, Werner B, et al Central nervous system infections following bone marrow transplantation: an autopsy report of 27 cases J Hematother Stem Cell Res 2000;9(4):535540 268 O’Sullivan DP Convulsions associated with cyclosporin A Br Med J (Clin Res Ed) 1985;290(6471):858 269 Appleton RE, Farrell K, Teal P, Hashimoto SA, Wong PK Complex partial status epilepticus associated with cyclosporin A therapy J Neurol Neurosurg Psychiatry 1989;52(9):1068-1071 270 Fischman MA, Hull D, Bartus SA, Schweizer RT Valproate for epilepsy in renal transplant recipients receiving cyclosporine Transplantation 1989;48(3):542 271 Yazal Erdem A, Azik F, Tavil B, Teber S, Tunc B, Uckan D Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy Pediatr Transplant 2014;18(4):412-413 272 Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai V Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation Pediatr Blood Cancer 2012;59(4):762-764 273 Cordelli DM, Masetti R, Bernardi B, et al Status epilepticus as a main manifestation of posterior reversible encephalopathy syndrome after pediatric hematopoietic stem cell transplantation Pediatr Blood Cancer 2012;58(5):785-790 274 Cordelli DM, Masetti R, Ricci E, et al Life-threatening complications of posterior reversible encephalopathy syndrome in children Eur J Paediatr Neurol 2014;18(5):632-640 275 Maude SL, Shpall EJ, Grupp SA Chimeric antigen receptor T-cell therapy for ALL Hematology Am Soc Hematol Educ Program 2014;2014(1):559-564 276 Einsiedel HG, von Stackelberg A, Hartmann R, et al Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87 J Clin Oncol 2005;23(31):7942-7950 277 Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data J Clin Oncol 2006;24(36):5750-5762 278 Tallen G, Ratei R, Mann G, et al Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 J Clin Oncol 2010;28(14):2339-2347 279 Roy A, Cargill A, Love S, et al Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial Br J Haematol 2005;130(1):67-75 280 Freyer DR, Devidas M, La M, et al Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children’s Oncology Group Blood 2011;117(11):3010-3015 281 Nguyen K, Devidas M, Cheng SC, et al Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study Leukemia 2008;22(12):2142-2150 282 Maude SL, Frey N, Shaw PA, et al Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 2014; 371(16):1507-1517 283 Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase dose-escalation trial Lancet 2015;385(9967):517-528 284 Maude SL, Laetsch TW, Buechner J, et al Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 2018;378:439-448 285 Davila ML, Riviere I, Wang X, et al Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 2014;6(224):224ra25 286 Neelapu SS, Tummala S, Kebriaei P, et al Chimeric antigen receptor T-cell therapy-assessment and management of toxicities Nat Rev Clin Oncol 2018;15(1):47-62 287 Maude SL, Barrett D, Teachey DT, et al Managing cytokine release syndrome associated with novel T cell-engaging therapies Cancer J 2014;20(2):119-122 288 Lee DW, Santomasso BD, Locke FL, et al ASBMT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells Biol Blood Marrow Transplant 2018;1-14 289 Teachey DT, Lacey SF, Shaw PA, et al Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia Cancer Discov 2016;6(6):664-679 290 Turtle CJ, Hanafi LA, Berger C, et al CD19 CAR-T cells of defined CD41:CD81 composition in adult B cell ALL patients J Clin Invest 2016;126(6):2123-2138 291 Chen F, Teachey DT, Pequingnot E, et al Measuring serum IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy J Immunol Methods 2016;434:1-8 292 Turtle CJ, Riddell SR, Maloney DG CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies Clin Pharmacol Ther 2016;100(3):252-258 293 Taraseviciute A, Tkachev V, Ponce R, et al Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates Cancer Discov 2018;8(6):750-763 294 Gust J, Hay KA, Hanafi LA, et al Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells Cancer Discov 2017; 7(12):1404-1419 295 Traube C, Silver G, Kearney J, et al Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU Crit Care Med 2014;42:656-663 296 Mahadeo KM, Khazal SJ, Abdel-Azim H, et al Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy Nat Rev Clin Oncol 2019;16:45-63 297 Senior M CAR-T death strikes Kite Nat Biotechnol 2017;35(6) e9 Abstract: Hematopoietic cell transplantation (HCT) has evolved as treatment for a variety of congenital and acquired malignant and nonmalignant disorders Patients undergoing HCT are at high risk for cardiac, respiratory, gastrointestinal, neurologic, immune and infectious complications that may require a stay in the pediatric intensive care unit Chimeric antigen receptor T-cell (CART) therapy is a form of cancer treatment that uses genetically modified T cells to target specific cell markers on tumor cells, resulting in tumor cell activation and killing CART therapy is associated with substantial acute complications, namely, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome Key words: Hematopoietic cell transplant (HCT), cardiac toxicity, periengraftment respiratory distress syndrome (PERDS), idiopathic pneumonia syndrome (IPS), venoocclusive disease (VOD), graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy (TA-TMA), chimeric antigen receptor T-cell (CART) therapy ... Dieks D, et al CMV-, EBV- and ADVspecific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome Biol Blood Marrow Transplant 2013;19(10):1480-1492... transplant (HCT), cardiac toxicity, periengraftment respiratory distress syndrome (PERDS), idiopathic pneumonia syndrome (IPS), venoocclusive disease (VOD), graft-versus-host disease (GVHD), transplant-associated